-
Mashup Score: 11IASLC Lectureships Honor the Work of Thoracic Oncology Trailblazers - ILCN.org (ILCN/WCLC) - 14 hour(s) ago
Nine difference-makers in the field of lung cancer shared their groundbreaking work during the IASLC Lectureship Awards presentations at WCLC 2024.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Data Shows Screening Programs Can Shift Stage Distribution at Diagnosis - ILCN.org (ILCN/WCLC) - 2 day(s) ago
Dr. Mike Gieske said since implementing a multidisciplinary screening approach, his healthcare system has seen a 19% decrease in late-stage lung cancers, and they now see more early-stage than late-stage lung cancers.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Did you know that screening programs can shift stage distribution at the time of diagnosis? Visit ILCN to read the data presented at #WCLC24: https://t.co/7EjmSm9hNw #LCSM
-
-
Mashup Score: 11FDA Approval: TTFields for NSCLC | IASLC - 2 day(s) ago
Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to divide. TTFi …
Source: www.iaslc.orgCategories: General Medicine News, Oncologists1Tweet-
🎙️ New episode of #LungCancerConsidered! @NarjustFlorezMD & @LealTiciana dive into Tumor Treating Fields (TTFields), an FDA-approved therapy disrupting cancer cell division. Learn about the Phase III LUNAR study! Listen now: https://t.co/tIhqtd6E2r #LCSM #LungCancer https://t.co/Nra4snKD00
-
-
Mashup Score: 1
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Check out the latest findings from the BR.31 trial that were presented at the 2024 ESMO Congress. Visit ILCN for a recap: https://t.co/9m04FwICcv #LCSM
-
-
Mashup Score: 2IASLC's Regional Course Series | IASLC - 14 day(s) ago
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies.
Source: www.iaslc.orgCategories: General Medicine News, Oncologists1Tweet-
Unlock the Power of Liquid Biopsy in Lung Cancer Care in LATAM! Join top LATAM experts for insights on cutting-edge applications across every stage of lung cancer. 📅 Choose Your Session: Nov 19 | 3:00 p.m. MDT Nov 21 | 4:00 p.m. MDT REGISTER NOW: https://t.co/pk2pJ9lclp https://t.co/TgE4YzU9VX
-
-
Mashup Score: 2Older Age Alone Does Not Preclude Benefit From Early Detection - ILCN.org (ILCN/WCLC) - 15 day(s) ago
Dr. Matt Warkentin says in those without significant comorbidity and who are fit for surgery, screening may provide survival benefits.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet-
Should age just be a number when it comes to lung cancer screening? Read the latest insights shared at #WCLC24 in ILCN: https://t.co/FCMwqmxZtD #LCAM
-
-
Mashup Score: 5Novel ALK-Selective TKI Looks Promising Based on Findings From ALKOVE-1 Trial - ILCN.org (ILCN/WCLC) - 16 day(s) ago
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
The latest from #WCLC24: Findings from the phase I ALKOVE-1 trial indicate novel ALK-selective TKI looks promising. Read more in ILCN: https://t.co/fxmo7bnlTa #LCAM
-
-
Mashup Score: 1Zidesamtinib Demonstrates Promising Response in ROS1-Positive NSCLC - ILCN.org (ILCN/WCLC) - 19 day(s) ago
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
#WCLC24 Updates: Zidesamtinib showed encouraging clinical activity in ROS1-positive NSCLC. Learn more in ILCN: https://t.co/FOQfmRwR0I #LCAM
-
-
Mashup Score: 1High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study - 19 day(s) ago
Leptomeningeal metastasis (LM) is one of the most severe complications of NSCLC. Furmonertinib is a pan-EGFR tyrosine kinase inhibitor (TKI) with a high rate of brain penetration and a wide therapeutic window. Here, we evaluated the efficacy and safety of high-dose furmonertinib in patients with EGFR-mutated NSCLC and LM.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Seeing as furmonertinib is a pan-EGFR TKI w/a wide therapeutic window, the authors evaluated the efficacy/safety of the treatment in pts w/EGFR-mutated #NSCLC & LM. They found that high-dose treatment may have clinical efficacy & tolerable safety in pts. https://t.co/UjXbHKf6lB https://t.co/7OWZdn6BuK
-
-
Mashup Score: 10LALCA 2024 Highlights | IASLC - 21 day(s) ago
In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses the future of lung cancer research in Brazil and the largest lung cancer screening …
Source: www.iaslc.orgCategories: General Medicine News, Oncologists1Tweet-
In this episode, host @NarjustFlorezMD discusses the future of #lungcancer research in Brazil & the largest lung cancer screening program in S. America. Recorded during #LALCA24 in Bogota, w/guests @cbaldotto & Dr. Francisco Sarmiento. Listen Now: https://t.co/Z2MkQ3cdDR #LCSM https://t.co/84AOfSZKC3
-
The IASLC Lectureship Awards recognized nine pioneers in the field of lung cancer during #WCLC24. You can read the full story in ILCN: https://t.co/UEfRHaicyE #LCSM